Biomarkers Market: Growth, Size, Share, and Trends

Report Code BT 2120
Published in May, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

Overview

The global biomarkers market, valued at US$58.07 billion in 2024, stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period. This growth is supported by the growing use of biomarkers in drug development and the increasing role of companion diagnostics in advancing precision medicine. The rising number of cancer cases worldwide and increased funding for various types of research are other important factors propelling the market's growth. Moreover, advances in omics technologies, including genomics and proteomics, are now enabling the development of more sophisticated tests based on biomarkers. Many companies are now targeting new markets such as the Asia Pacific region, where there is a high demand for targeted diagnostics, thus creating new opportunities for biomarker-driven solutions.

Biomarkers Market – Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Biomarkers Market

Asia Pacific

The growth of the Asia Pacific market is primarily due to the rising research funding for novel therapies in the region.

Growth in this market is primarily driven by high cancer incidence and increasing pharmaceutical research funding.

Rising drug development activity has propelled the demand for biomarkers.

Issues related to high pricing associated with biomarkers are restraining the market growth.

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. Rising public investments in R&D drive market growth.

Global Biomarkers Market Dynamics

DRIVER: Advancements in omics technology

Advancements in omics technologies drive growth in the biomarkers market by enabling precise identification of disease biomarkers and drug targets. Genomic, epigenomic, transcriptomic, proteomic, and metabolomic studies reveal disease-related molecular changes, aiding diagnosis, prognosis, and treatment design. Companies are utilizing these technologies to enhance biomarker discovery and drug development. For example, Crown Bioscience employs genomics and AI-driven analytics for data-driven biomarker discovery in oncology. Revvity provides solutions using multiplex and multi-omic approaches to analyze DNA, RNA, and protein biomarkers. In April 2025, Vizgen expanded its spatial proteomics tools with OmniVUE panels for Antibody-Drug Conjugate development. Momentum Biotechnologies also acquired OmicScouts GmbH in March 2025 to enhance its European proteomics-based services. These technologies significantly improve the identification and validation of disease markers and drug targets, accelerating drug discovery and precision medicine.

RESTRAINT: Disease complexity and heterogeneity

One of the major constraints of the biomarkers market is the complexity and variability of diseases. Diseases often involve multiple molecular pathways and show different symptoms in different patients, making it hard to identify biomarkers that work for everyone. These differences mean a biomarker effective in one patient group may not work in another. Diseases also change over time, so biomarkers need to detect these changes, which further complicates their development and approval. Additionally, there are no standard methods for discovering and validating biomarkers, leading to inconsistent results. The high cost and lengthy development timelines for biomarkers also limit progress. Regulatory requirements for clinical testing and approval add further delays. These factors slow down the use of biomarkers in regular healthcare.

 

OPPORTUNITY: Shift towards personalized medicine and precision oncology

The shift towards precision medicine and oncology presents significant growth opportunities in the biomarkers market. This approach tailors treatments to individual patient profiles, requiring accurate biomarkers to guide therapy decisions. Industry leaders are capitalizing on this trend by enhancing diagnostic tools and companion diagnostics (CDx). For instance, in September 2024, Agilent Technologies launched a CLIA-certified Biopharma CDx Services Lab in the U.S. to expedite companion diagnostic development and reduce the timeline from clinical trials to FDA approval. Currently, there are over 60 FDA-approved companion diagnostic tests, primarily in oncology, to identify patients who may benefit from targeted treatments. However, most focus on single biomarkers, limiting their effectiveness in capturing tumor heterogeneity, which presents an opportunity for more comprehensive diagnostics.

CHALLENGES: Complexities associated with the integration of data sets

The integration of complex data sets in biomarkers research presents significant challenges to market growth. Biomarker data is generated from various platforms, including traditional blood tests, next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH). This results in large volumes of diverse and rapidly growing information. The lack of standardized reporting protocols, especially for NGS data, complicates data interpretation and limits comparability across organizations and testing methods. Additionally, disparities in biomarker testing among racial, ethnic, and economic groups reduce data accessibility and completeness. Limited healthcare plan coverage and unequal clinical trial participation hinder the availability of comprehensive and representative biomarker datasets.

Global Biomarkers Market Ecosystem Analysis

The ecosystem for the biomarkers market comprises major players offering biomarker products & services, regulatory authorities, and end users, such as academic & research institutes, hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, and other end users. These stakeholders interact and collaborate to drive growth and innovation in the biomarker landscape.

Biomarkers Market Ecosystem
 

Assay kits held the largest market share in the biomarkers market, by offering, in 2024.

The biomarkers market is segmented into consumables, services, and software based on offering. The consumables segment is further divided into assay kits, chemicals & reagents, and columns & filters. In 2024, assay kits held the largest share of the biomarker consumables market. The large share of these consumables can be attributed to their wide application across various fields such as clinical diagnostics, research, and drug development. These kits offer standardized protocols for accurate and efficient detection and analysis of biomarkers in different biological samples, supporting various diagnostic and research applications. Moreover, developments such as the launch of novel biomarker-based assays, such as the October 2024 launch of Thermo Fisher’s Ion Torrent Oncomine Dx Target Test and the May 2025 launch of Roche’s VENTANA MET (SP44) RxDx Assay, highlight the growing focus of key players towards this consumable class.

Clinical diagnostics held the largest share in the biomarkers market, by application, in 2024.

Based on applications, the biomarkers market is segmented into clinical diagnostics, drug discovery & development, personalized medicine, clinical research, and other applications. In 2024, clinical diagnostics applications held the largest share in the biomarkers market. This large share of this application segment can be attributed to the growing use of biomarkers for disease detection, prognosis, and diagnosis in clinical settings. Biomarker-based tests, such as blood-based assays, genetic panels, and imaging biomarkers, are being increasingly adopted in standard diagnostic workflows. Moreover, the growing use of companion diagnostics for precision oncology has further expanded the clinical utility of biomarkers. Additionally, increasing focus on preventive healthcare, supported through reimbursement for diagnostic tests in many developed regions, has contributed to high demand in this segment.

North America was the dominant region in the biomarkers market in 2024.

Based on region, the biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America held the largest market share of the biomarkers market. This large share can be attributed to its well-established healthcare infrastructure, high R&D spending, and the existence of key industry players and research centers. The Asia Pacific region is expected to grow at the highest rate during the forecast period, supported by its fast-growing healthcare market, increasing prevalence of chronic diseases, and ongoing government efforts toward life science research promotion.

HIGHEST CAGR MARKET IN 2025–2030
US: FASTEST-GROWING MARKET IN THE REGION
Biomarkers Market Region

Recent Developments of Biomarkers Market

  • In May 2025, F. Hoffmann-La Roche Ltd received FDA approval for its Elecsys PRO-C3 test, a biomarker-based diagnostic tool developed with Nordic Bioscience to evaluate liver fibrosis severity in patients with MASLD (metabolic dysfunction–associated steatotic liver disease)
  • In April 2025, Eurofins Scientific acquired SYNLAB’s clinical diagnostics operations in Spain, expanding its capabilities in molecular diagnostics, essential for biomarker discovery, validation, and clinical application
  • In January 2025, Thermo Fisher Scientific, Inc. partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the world’s largest biomarker-focused proteomics study.
  • In September 2024, QIAGEN partnered with Lilly to develop a QIAstat-Dx in vitro diagnostic (IVD) panel for detecting APOE genotypes, used in diagnosing Alzheimer’s disease.

Key Market Players

Want to explore hidden markets that can drive new revenue in Biomarkers Market?

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered Offering, Type, Research Area, Technology, Disease Indication, Application, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Frequently Asked Questions(FAQ)

What are the opportunities for growth in the biomarkers industry?

The adoption of biomarker technologies in emerging countries presents significant growth opportunities for the biomarkers market.

Which disease indication dominated the biomarkers market in 2024?

In 2024, cancer held the largest share of the biomarkers market by disease indication.

Which biomarker-related offerings are expected to witness the highest growth during the forecast period?

Consumables are expected to witness the highest growth during the forecast period.

Which end-user segment is expected to witness the highest growth in the biomarkers market during the forecast period?

Pharmaceutical and biotechnology companies are expected to register the highest growth during the forecast period.

What is the market size for the biomarkers market in 2025?

The global biomarkers market is expected to grow from USD 62.39 billion in 2025 to USD 104.15 billion by 2030, at a CAGR of 10.8%.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
13
RESEARCH METHODOLOGY
45
EXECUTIVE SUMMARY
67
PREMIUM INSIGHTS
114
MARKET OVERVIEW
167
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022-2024
    AVERAGE SELLING PRICE RANGE, BY REGION, 2024
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - IMMUNOASSAYS
    - NGS
    - PCR
    - IN SITU HYBRIDIZATION
    - MICROARRAYS
    - MASS SPECTROMETRY
    COMPLIMENTARY TECHNOLOGIES
    - LIQUID BIOPSY
    - CRISPR
    ADJACENT TECHNOLOGIES
    - ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML)
    - SENSORS (WEARABLE DEVICES)
  • 5.8 PATENT ANALYSIS
  • 5.9 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.10 REGULATORY LANDSCAPE
    REGULATORY FRAMEWORK
    REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
  • 5.11 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITION RIVALRY
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA FOR END USERS
  • 5.13 INVESTMENT AND FUNDING SCENARIO
  • 5.14 IMPACT OF AI/ GEN AI ON BIOMARKER MARKET
  • 5.15 IMPACT OF US TARIFF ON BIOMARKER MARKET
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRY/REGION
    IMPACT ON END USER
  • 5.16 HS CODE (382200): DIAGNOSTIC OR LABORATORY REAGENTS, 2021-2024
    EXPORT SCENARIO
    IMPORT SCENARIO
BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
205
  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    ASSAY KITS
    REAGENTS & CHEMICALS
    OTHER CONSUMABLES
  • 6.3 SERVICES
  • 6.4 SOFTWARE
BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
228
  • 7.1 INTRODUCTION
  • 7.2 SAFETY BIOMARKERS
  • 7.3 EFFICACY BIOMARKERS
    PREDICTIVE BIOMARKERS
    SURROGATE BIOMARKERS
    PHARMACODYNAMICS BIOMARKERS
    PROGNOSTIC BIOMARKERS
  • 7.4 VALIDATION BIOMARKER
BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
278
  • 8.1 INTRODUCTION
  • 8.2 GENOMICS
  • 8.3 PROTEOMICS
  • 8.4 METABOLOMICS
  • 8.5 OTHER RESEARCH AREA
BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
345
  • 9.1 INTRODUCTION
  • 9.2 IMMUNOASSAYS
    ELISA
    WESTERN BLOT
    PROTEIN MICROARRAY
  • 9.3 PCR
  • 9.4 MASS SPECTROMETRY
  • 9.5 NGS
  • 9.6 CHROMATOGRAPHY
  • 9.7 OTHER TECHNOLOGIES
BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
398
  • 10.1 INTRODUCTION
  • 10.2 CANCER
  • 10.3 INFECTIOUS DISEASES
  • 10.4 IMMUNOLOGICAL DISORDERS
  • 10.5 NEUROLOGICAL DISORDERS
  • 10.6 CARDIOVASCULAR DISORDERS
  • 10.7 OTHER DISEASE INDICATION
BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
456
  • 11.1 INTRODUCTION
  • 11.2 CLINICAL DIAGNOSTICS
  • 11.3 DRUG DISCOVERY & DEVELOPMENT
  • 11.4 PERSONALIZED MEDICINE
  • 11.5 CLINICAL RESEARCH
  • 11.6 OTHER APPLICATIONS
  • 11.7 INTRODUCTION
  • 11.8 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.9 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 11.10 ACADEMIC & RESEARCH INSTITUTES
  • 11.11 OTHER END USERS
  • 11.12 INTRODUCTION
  • 11.13 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    CANADA
  • 11.14 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    UK
    FRANCE
    ITALY
    SPAIN
    REST OF EUROPE
  • 11.15 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    CHINA
    INDIA
    SOUTH KOREA
    AUSTRALIA
    REST OF ASIA PACIFIC
  • 11.16 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    MEXICO
    REST OF LATIN AMERICA
  • 11.17 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - UNITED ARAB EMIRATES (UAE)
    - SAUDI ARABIA (KSA)
    - REST OF GCC COUNTRIES
    REST OF MIDDLE EAST
  • 11.18 AFRICA
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
545
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE ANALYSIS, 2022–2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - OFFERING FOOTPRINT
    - TECHNOLOGY FOOTPRINT
    - APPLICATION FOOTPRINT
  • 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - DETAILED LIST OF KEY STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 12.7 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EAPANSIONS
  • 12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 12.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE BIOMARKERS MARKET
COMPANY PROFILES
589
  • 13.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    ABBOTT
    MERCK KGAA
    F. HOFFMANN-LA ROCHE LTD
    QIAGEN
    REVVITY
    LABORATORY CORPORATION OF AMERICA HOLDINGS
    CHARLES RIVER LABORATORIES
    BIO-RAD LABORATORIES, INC.
    EUROFINS SCIENTIFIC
    BIOMÉRIEUX
    AGILENT TECHNOLOGIES, INC.
    JSR CORPORATION
    QUANTERIX
    MESO SCALE DIAGNOSTICS, LLC.
    GUARDANT HEALTH
  • 13.2 OTHER PLAYERS
    CELERION
    STANDARD BIOTOOLS
    ZEUS SCIENTIFIC, INC.
    BIOAGILYTIX
    STRESSMARQ BIOSCIENCES INC.
    NORTHEAST BIOANALYTICAL LABORATORIES LLC
    SIGNOSIS
    SERIMMUNE
    THERAINDX LIFESCIENCES PVT. LTD.
    SYNEXA LIFE SCIENCES BV
    DIATECH PHARMACOGENETICS
    SINGULEX, INC.
    R-BIOPHARM AG
    DIAMETRA
APPENDIX
601
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

 

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biomarkers market. The secondary sources used for this study include American Society of Clinical Oncology (ASCO), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organization (CDSCO), Center for Disease Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), Chinese Medical Journal, Clinicaltrials.gov.in, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), Organization for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, World Health Organization (WHO), Corporate and Regulatory Filings, Annual Reports, Sec Filings, Investor Presentations, and Financial Statements; Business Magazines & Research Journals; Press Releases, MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global biomarkers market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & and biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Biomarkers Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the biomarkers market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the biomarkers market business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach

  • After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Biomarkers Market

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Market Definition

A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes. The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery and development, personalized medicine, and clinical research. It also studies the adoption of biomarkers across key research areas, such as oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type of biomarkers, including safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarker landscape.

Stakeholders

  • Academic & Research Institutes
  • Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
  • Contract Research Organizations (CROs)
  • Biomarkers Service & Software Providers
  • Diagnostics Companies
  • Market Research and Consulting Firms
  • Pharmaceutical and Biotechnology Companies
  • Regulatory Agencies
  • Venture Capitalists
  • Forensics Labs
  • Government organizations
  • Private research firms
  • Contract development and manufacturing organizations (CDMOs)
  • Hospitals and Diagnostic Laboratories

Report Objectives

  • To define, describe, and forecast the global biomarkers market based on offering, type, research area, technology, disease indication, application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments in six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the global biomarkers market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
  • To benchmark players in the biomarkers market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share

 

Previous Versions of this Report

Biomarkers Market Size by Product & Service (Consumable, Service, Software), Type (Safety, Efficacy, Validation), Disease (Cancer, Infectious, Neurological), Application (Diagnostics, Drug Discovery, Personalized Medicine), Region - Global Forecast to 2028

Report Code BT 2120
Published in Apr, 2024, By MarketsandMarkets™

Biomarkers Market by Product (Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global Forecast to 2026

Report Code BT 2120
Published in Feb, 2023, By MarketsandMarkets™

Biomarkers Market by Product (Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global Forecast to 2026

Report Code BT 2120
Published in Jul, 2021, By MarketsandMarkets™

Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021

Report Code BT 2120
Published in Feb, 2017, By MarketsandMarkets™

Biomarkers Market by Product (Consumables, Services), by Type (Predictive, Pharmacodynamic, Safety), Application (Diagnostics, Drug Discovery, Personalized Medicine), Disease Indication (Cardiovascular, Immunological) - Global Forecast to 2020

Report Code BT 2120
Published in Jul, 2015, By MarketsandMarkets™

Biomarkers Market - by Discovery Technologies & Applications - 2018 | MarketsandMarkets

Report Code BT 2120
Published in Sep, 2013, By MarketsandMarkets™

Biomarkers Market - by Discovery Technologies & Applications - 2018 | MarketsandMarkets

Report Code BT 2120
Published in Jan, 2012, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Biomarkers Market

Patrick

Mar, 2022

Looking forward to gain more insights on the global Biomarkers Market.

Raymond

Mar, 2022

What are the growth opportunities in Biomarkers Market?.

Jack

Mar, 2022

Can you enlighten us on the end users in Biomarkers Market?.

DMCA.com Protection Status